menu

Schizophrenia and Bipolar Disorder: Improving Adherence and New Therapeutic Updates

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Schizophrenia and Bipolar Disorder: Improving Adherence and New Therapeutic Updates

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Schizophrenia affects an estimated 21 million people worldwide, and bipolar disorder (BPD) is the sixth leading cause of disability. These are chronic psychiatric illnesses that require long-term care, and place significant health and economic burdens on patients and their families. In recent decades, the distinct separation of these two illnesses has weakened, and the medical literature now recognizes a partial genetic overlap between schizophrenia and BPD. Unfortunately, both schizophrenia and BPD are difficult to treat and are associated with substantial morbidity and mortality, particularly when sub-optimally treated. Lack of consistent adherence to treatment is a significant issue; however, newer formulations have recently been approved and emerging therapies are on the horizon.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

    *Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    All relevant relationships have been mitigated. The following disclosures were made:

    Joseph F. Goldberg, MD has disclosed the following relevant financial relationships:
    Alkermes Inc.; Axsome Therapeutics; American Psychiatric Publishing; BioXcel Therapeutics; Cambridge University Press; Intra-Cellular Therapies; Jazz Pharmaceuticals; Lundbeck; Neurelis; Neumora; Otsuka; Sage Therapeutics; Supernus Pharmaceuticals; Sunovion

    John J. Russell, MD (host) has disclosed the following relevant financial relationships:
    Speaker and Advisory Board Member: Bayer; GlaxoSmithKline; Pfizer; Sanofi

    The following reviewers/planners/authors have reported no real or apparent conflicts with ineligible companies.

    Susan Tyler, PhD, CME Director

    Bruce Gebhardt, MD, CME Reviewer

    Heather Muskopf, Program Manager

    Otto Ratz, MD

    Christina Culbert

  • Target Audience

    The intended audiences for this activity are physicians and other health care professionals who manage patients with schizophrenia and bipolar disorder.

  • Learning Objectives

    • Recognize risk factors to improve adherence associated with schizophrenia and/or bipolar disorder;
    • Identify newer and emerging agents seeking to improve outcomes in patients with schizophrenia and/or bipolar disorder;
    • Assess strategies and techniques to collaboratively engage in shared decision making in schizophrenia and bipolar disorder.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This CME activity is supported by an educational grant from Alkermes and Intra-Cellular Therapeutics, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Schizophrenia affects an estimated 21 million people worldwide, and bipolar disorder (BPD) is the sixth leading cause of disability. These are chronic psychiatric illnesses that require long-term care, and place significant health and economic burdens on patients and their families. In recent decades, the distinct separation of these two illnesses has weakened, and the medical literature now recognizes a partial genetic overlap between schizophrenia and BPD. Unfortunately, both schizophrenia and BPD are difficult to treat and are associated with substantial morbidity and mortality, particularly when sub-optimally treated. Lack of consistent adherence to treatment is a significant issue; however, newer formulations have recently been approved and emerging therapies are on the horizon.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

    *Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    All relevant relationships have been mitigated. The following disclosures were made:

    Joseph F. Goldberg, MD has disclosed the following relevant financial relationships:
    Alkermes Inc.; Axsome Therapeutics; American Psychiatric Publishing; BioXcel Therapeutics; Cambridge University Press; Intra-Cellular Therapies; Jazz Pharmaceuticals; Lundbeck; Neurelis; Neumora; Otsuka; Sage Therapeutics; Supernus Pharmaceuticals; Sunovion

    John J. Russell, MD (host) has disclosed the following relevant financial relationships:
    Speaker and Advisory Board Member: Bayer; GlaxoSmithKline; Pfizer; Sanofi

    The following reviewers/planners/authors have reported no real or apparent conflicts with ineligible companies.

    Susan Tyler, PhD, CME Director

    Bruce Gebhardt, MD, CME Reviewer

    Heather Muskopf, Program Manager

    Otto Ratz, MD

    Christina Culbert

  • Target Audience

    The intended audiences for this activity are physicians and other health care professionals who manage patients with schizophrenia and bipolar disorder.

  • Learning Objectives

    • Recognize risk factors to improve adherence associated with schizophrenia and/or bipolar disorder;
    • Identify newer and emerging agents seeking to improve outcomes in patients with schizophrenia and/or bipolar disorder;
    • Assess strategies and techniques to collaboratively engage in shared decision making in schizophrenia and bipolar disorder.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This CME activity is supported by an educational grant from Alkermes and Intra-Cellular Therapeutics, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule29 Feb 2024